Contact

UK Office

Only Medics
33 Blagrave Street
Reading, Berkshire
RG1 1PW, UK

Tel -
+44(0)1189 522799

Email -
info@onlymedics.com

EU Office

Only Medics
Quantum House
22 - 24 Red Lion Court
Fleet Street, London
EC4A 3EB, UK

Tel -
+44(0)2078 221719

Share &
Connect

Keep connected & join the Only Medics Network here.

LinkedIn Facebook Twitter

Specialist Sectors

  • AstraZeneca announces new Cambridge Biomedical Campus

    Jun 18, 2013 Pharmaceutical giant AstraZeneca has announced it is setting up its new global headquarters, just south of Cambridge. The £330million research and development site will employ a skilled workforce of 2,000 people and will open by 2016. Research and Development will cease at Alderley Park in Ch...

  • If 8 areas of NHS activity were improved then vast amounts of money for CCGS could be saved

    Jun 12, 2013 If the National Health Service improved just 8 areas of their activity then 212 of England’s Clinical Commissioning Groups (CCGs) would save more than £1.6 billion. Statistics were analysed in research by consultancy MedeAnalytics. This covers all patient-level activity and associat...

  • Diabetes UK and Tesco Diets team up to raise awareness for healthy eating

    Jun 05, 2013 The major supermarket Tesco is forming an alliance with the charity Diabetes UK, to raise £10 million to create healthier communities to help those affected by or at risk of Diabetes. This alliance is recognising their shared views and opinions which have a common aim to help those affe...

  • Only Medics London office move to Bouverie Street

    May 23, 2013 Only Medics London office move to Bouverie StreetOn Friday May 24th, our London office will be moving from its current location in its offices in Quantum House, to 11-12 Bouverie Street. This move will more than double the office space from 700sq ft, to a new much bigger environment of 1,600sq ft &n...

  • Icon Release Strong Q1 Results

    Apr 29, 2013 Icon continued their run of solid quarterly results, reporting an operating income of US $23.0 million, an increase of 96.0% year on year.  Net revenues were also higher, at US $316.8 million. The income total included reorganisation, and other items amounting to US $4.41 million.  Withou...

  • Royalty Pharma’s Offer Rejected by Elan

    Apr 22, 2013 Elan Corp have confirmed that they have declined Royalty Pharma’s $11.25 per share acquisition bid, adding that the bid does not come near to what the drug maker is worth. Last week, Royalty decreased their bid from a previous offer which could have reached as high as $12, depending upon the ...

  • Royalty Increases Pressure on Elan with Superior Offer

    Apr 15, 2013 Royalty Pharma have increased their bid to acquire Elan Corp, in a move that values the Irish drug maker to up to $7.30 billion. After being asked by the Irish Takeover Panel to make a tangible offer by May 10th or abandon their plans to buy Elan, Royalty has made what they describe as a “fir...

  • European Pharmaceutical 2013 Salary Survey

    Apr 10, 2013 Do you earn the correct amount? As part of the Clinical Professionals Group, Only Medics are launching a European salary survey to determine the salary and benefits for European pharmaceutical physicians. The salary survey consists of questions concerning your career and how satisfied you are with...

  • AstraZeneca Acquires AlphaCore Pharma

    Apr 02, 2013 AstraZeneca have today announced that they are expanding their cardiovascular and metabolic disease pipeline with the acquisition of AlphaCore Pharma. AlphaCore are a Michigan-based biotechnology company focused on the development of ACP-501, a recombinant human lecithin-cholesterol acyltransferase...

  • Cancer Research Technology, the Institute of Cancer Research and Janssen Partner for Myeloma Drug

    Mar 21, 2013 Cancer Research Technology (CRT) and the Institute of Cancer Research (ICR) announced earlier today that they have partnered with Johnson & Johnson unit, Janssen Biotech, in an agreement to discover a potential new drug for the blood cancer, multiple myeloma. The partnership is aiming to identi...

  • Drug Prices Could be Cheaper, Claims GSK Chief

    Mar 18, 2013 Prices of medicines should be lower and the high cost of research is a myth, according to GlaxoSmithKline’s boss Sir Andrew Witty. The pharmaceutical industry should be able to charge less for new drugs in the future by passing on efficiencies within R&D to their customers, according to t...

  • Only Medics to Attend DGPharMed 2013

    Mar 12, 2013 Only Medics will be attending DGPharMed’s annual conference at the Hotel Concorde, Berlin, Germany on the 14th and 15th March 2012. 2013 sees the 29th year of the annual conference by the German Society of Pharmaceutical Medicine. The conference starts at 9:20am, and finishes the following d...

  • Only Medics Relocate to New UK Office!

    Mar 11, 2013 As part of our continued expansion, Only Medics have relocated to a new larger UK office, having outgrown our previous office. The new office is over double the size of the previous UK office, allowing Only Medics to continue growing to fit your future needs. Our new office is located at: 3rd F...

  • Only Medics to Attend the 2013 BrAPP Conference

    Mar 01, 2013 Only Medics will be attending this year’s BrAPP Annual Symposium on 7th March 2013 in Royal College of Pathologists. The conference will start at 9am, and will conclude at 5pm with the BrAPP AGM for BrAPP members. The conference offers attendees the chance to opportunity to network with fell...

  • Warner Chilcott Q4 Net Income Increases 37.8%

    Feb 25, 2013 Warner Chilcott has announced that their fourth-quarter net income grew 37.8%, although pharmaceutical sales were hit by the impact of generic competition for their osteoporosis drug, Actonel. The organisation’s net income increased to $124 million, or 49 cents per share, up from $90 million,...

  • CROMSOURCE Expands in Poland

    Feb 20, 2013 CROMSOURCE, which was formed roughly two years ago as a result of the acquisition of MSOURCE by CROM, has combined it’s presence in Poland with a new office in Warsaw. When CROM acquired MSOURCE, the latter contract research organisation (CRO) had been internationally active since 1994. Dr O...

  • Roche and Chiasma Sign $585 Million Deal

    Feb 18, 2013 Roche has teamed up with Chiasma to develop and market Octreolin, Chiasma’s investigational treatment for growth hormone disorders. Octreolin is oral form of the peptide octreotide, a somatostatin analogue which is currently only commercially available by injection and is marketed by Novartis...

  • Tivozanib Matches Nexavar on Cancer Survival Rate

    Feb 14, 2013 Astellas and Aveo Pharmaceuticals have announced that the overall survival (OS) data for their kidney cancer drug, tivozanib, which demonstrates that it matches a key competitor. Two-year data from the TIVO-1 clinical study shows that there is no statistically significant difference in the overall ...

  • Sanofi Earnings Knocked by Generics

    Feb 07, 2013 Sanofi’s fourth quarter earnings have been hit by generics, although the majority of the patent cliff is now behind the French drugmaker, who anticipate a return to growth in the second half of 2013. Business net income, which excludes items, dropped 27.1% to 1.57 billion euros (at constant e...

  • Takeda Posts Q3 Financials, Boosted by Nesina and Pantoprazole Sales

    Feb 05, 2013 Takeda Pharmaceuticals have revealed reasonable financial results for the first nine months of their fiscal year, regardless of the major drop in sales of their diabetes drug, Actos. Japan’s largest drugmaker’s net income for the April-December period dropped 13.5% to 138.91 billion (ar...

  • Pfizer Release Q4 Financial and May Consider Splitting Their Drugs Unit

    Jan 30, 2013 Pfizer have released a reasonable set of financials despite the effects of generic competition to their cholesterol blockbuster drug, Lipitor. Fourth-quarter net income soared to $6.32 billion, up from $1.44 billion in the like-for-like quarter of the previous year.  The net income was boosted...

  • Watson Pharmaceuticals Renamed to Actavis and Announce Growth Strategy

    Jan 28, 2013 Watson Pharmaceuticals, the third-biggest generics drugmaker, have changed their name to Actavis and set out their growth plans. The company initially revealed intentions to change their name last year, succeeding the acquisition of the Actavis Group. The company has begun a multi-year rebranding ...

  • Allergan Purchases MAP Pharmaceuticals for $958m

    Jan 24, 2013 Allergan have agreed to pay $25 per share in a bid to purchase Mountain View's neurology group MAP Pharmaceuticals. The per share cash offer signifies a 60% premium over MAP’s closing stock price on January 22nd, and is equal to roughly $958 million. The merger agreement, which is expected t...

  • Johnson & Johnson’s Profits Boosted by Pharmaceutical Division

    Jan 23, 2013 Johnson & Johnson have announced an 8% rise in sales for their fourth quarter, aided by strong results from their pharmaceutical division. The group net income for the quarter was $2.57 billion, in comparison to $218 million in the fourth quarter of the previous year, when net income was affect...

  • Scotland Unveils £21m Fund for Rare Diseases

    Jan 16, 2013 A £21 million fund will been made available to pay for rare orphan drugs that are not currently recommended by the Scotland’s regulatory watchdog, the Scottish Medicines Consortium (SMC). The fund will launch in March, and run until April 2014.  It will help cover successful new In...

  • Amgen Partners with BIND in $180 Million Agreement

    Jan 09, 2013 Amgen has joined up with Bind Biosciences to develop a kinase inhibitor nanomedicine for treating a variety of solid tumours. The agreement provides the US biotech major with access to the technology at BIND, who has developed “a new class of highly selective targeted and programmable therape...

  • Ulcerative Colitis Drug Market to Reach $3.7 Billion by 2021

    Jan 03, 2013 Sales of medication to treat ulcerative colitis in seven key markets are expected to double over the next decade, reaching $3.7 billion by 2021, according new research. The rapid growth will be largely driven by two premium-priced tumour necrosis factor-alpha (TNF-alpha) inhibitors - Abbott/Eisai's...

  • Merry Christmas from Only Medics!

    Dec 24, 2012 We would like to wish all our clients and candidates a very merry Christmas and a happy new year!  Thank you for your business in 2012.  We look forward to working with you in 2013! Only Medics will be closed from the afternoon of the 24th December 2012 until the 2nd Janua...

  • Study Finds Antibiotics Ineffective for Coughs

    Dec 20, 2012 A recent study has found that the use of antibiotics to treat persistent coughs (not caused by pneumonia) is ineffective. The European study involved 2,061 patients with acute lower-respiratory-tract infections where pneumonia was not suspected, and the patients were randomised to receive either am...

  • ACM Global Expand EU Lab Facilities

    Dec 04, 2012 ACM Global Central Laboratory, the US-headquartered laboratory testing operation that raised its European profile in March 2009 by acquiring Pivotal Laboratories, have relocated their European laboratory to a bigger facility in York’s Hospital Fields Road. ACM Global confirmed that they have ...

  • GW Pharmaceuticals Announces Mixed Results

    Nov 29, 2012 GW Pharma has released mixed results for the year, with sales rising and profits decreasing, but the company continues to demonstrate potential in their R&D pipeline with inspiring data for a mid-stage, cannaboid-based diabetes drug. The organisation saw their sales for the year ending Sept...

  • Hunt Addresses ‘Overstretched’ GPs and Priorities for Change

    Nov 27, 2012 In his initial speech to primary care chiefs as Secretary of State for Health, Jeremy Hunt stressed his confidence in enlisting GPs at the centre of the new commissioning system, even though he acknowledged that GPs are being ‘overstretched’ already. Hunt informed delegates at the NHS A...

  • Bayer Withdraws Schiff Bidding Interest

    Nov 21, 2012 Bayer have declared that they are not going to follow plans to purchase American vitamins company, Schiff Nutrition International, four days after their $1.20 billion offer was beaten by Reckitt Benckiser. Roughly three weeks ago, Bayer announced a bid of $34 per share to acquire Schiff, but Reckit...

  • NHS hospital prescribing costs remain high

    Nov 15, 2012 New and expensive treatments are continuing to drive up NHS prescribing costs in England’s hospitals. This is according to a new IMS Health report, commissioned by the NHS, which found that hospital prescribing costs in England increased by 6.9% in 2011, far outstripping the 1.9% growth se...

  • Cancer Costs the UK £15.8 Billion per Year

    Nov 08, 2012 New research presented yesterday, claims that the total yearly price tag of all cancers to the UK economy is currently £15.8 billion, of which lung cancer accounts for £2.4 billion – far greater than any other type of the disease. The results of the research highlight the on-going...

  • Novo Nordisk Q3 Net Profit Grows 26%

    Nov 01, 2012 Novo Nordisk revealed more healthy sales figures yesterday for their third quarter results, aided by solid sales of their diabetes drug, Victoza, and its modern insulins. The company announced an 18% growth in sales to a total of 57.1 billion Danish kroner ($9.9 billion).  Operating profit inc...

  • NHS Satisfaction Decreases Amid Reforms and Cuts

    Oct 30, 2012 The reform of the National Health Service (NHS), alongside large funding cuts, is reducing people’s satisfaction with the NHS. This is according to the findings from the NHS Spring Public Perceptions of the NHS Tracker Survey, which was published on the weekend. The survey was led by the Ips...

  • AstraZeneca Announce 15% Sales Drop

    Oct 25, 2012 AstraZeneca have announced a dip of 15% for their Q3 sales, mainly as a result of the loss of exclusivity on several key brands, and costs relating to the disposal of their former Astra Tech and Aptium Oncology units. The Anglo-Swedish organisation’s revenue fell to $6.8 million in comparison...

  • UK Doctors To Have Regular Revalidation Assessments

    Oct 18, 2012 Jeremy Hunt announced today that UK doctors are to become the first in the world to have to take regular assessments to ensure they are fit for practise. The procedure, known as revalidation, will mean that British doctors will have regular assessments to confirm that their training and expertise a...

  • Depression Up 11.5% Over 3 Years

    Oct 17, 2012 The number of people suffering from depression in England has grown by almost half a million in just three years, according to a new report by SSentif Intelligence. Analysing the data from the NHS Quality Outcomes Framework, the group discovered that the number of registered patients with depressio...

  • Collaboration Best for Stretched NHS Budgets

    Oct 14, 2012 The Association of the British Pharmaceutical Industry (ABPI) head has noted that he understands that the UK National Health Service must save money, but wishes to create new partnerships to help this happen. Stephen Whitehead, chief executive of the ABPI, writing in the Guardian’s profession...

  • HRT Reduces Heart Attack Risk

    Oct 10, 2012 The dispute around the safety and benefits of taking HRT (hormone replace therapy) has taken another turn, after a study found that long-term use of the therapy considerably reduced heart attacks and heart failure, without raising the danger of cancer, blood clots or stroke. In the study, which was...

  • £200 Million Funding Increase for UK Scientific Research

    Oct 08, 2012 The UK government yesterday announced that they are contributing an additional £200 million to the Research Partnership Investment Fund to boost scientific research. As a result of the government support increasing to £300 million, the total investment is estimated to be a minimum of &p...

  • Rare Diseases Neglected and Misdiagnosed by NHS

    Oct 03, 2012 One in 17 people will be affected by a rare medical condition, but these conditions are too often neglected by the NHS, according to a recent report titled ‘Forgotten Conditions: misdiagnosed and unsupported, how patients are being let down’. This results in lower life quality for indiv...

  • Cancer Drugs Fund Opposed by British Public, Study Suggests

    Sep 30, 2012 A new study by the University of Bangor in North Wales has found that the British public do not support England’s Cancer Drugs Fund. The study asked over 4,000 people across England, Wales and Scotland if the NHS should pay extra for cancer drugs in comparison to medication for equally seriou...

  • Progenics Makes Further Job Cuts

    Sep 23, 2012 Progenics Pharmaceuticals are laying off more than a quarter of their workforce after failing to gain extended approval for their constipation drug, Relistor. The organisation noted that they are ending several early-stage research projects in order to concentrate on their cancer programmes, in par...

  • J&J Resolves ADHD Lawsuit with Impax Labs and Teva

    Sep 16, 2012 Johnson & Johnson (J&J) have established a new deal to settle a patent disagreement regarding their attention-deficit hyperactivity disorder (ADHD) drug, Concerta. Impax Laboratories and partner Teva Pharmaceutical Industries launched a lawsuit against Johnson & Johnson’s Janssen ...

  • Value-Based Pricing Discussions Passed to Jeremy Hunt

    Sep 05, 2012 The new UK health secretary Jeremy Hunt will be thrown into the deep end this month as he heads straight into negotiations over value-based pricing (VBT). Andrew Lansley, who was both the designer and lead for the value-based pricing discussions, was removed from the post of health secretary on Tue...

  • Agennix Cuts 55% of Jobs

    Aug 27, 2012 After the failure of their experimental lung cancer drug, talactoferrin, in a late-stage clinical trial, Germany's Agennix announced on Friday that they are reducing their workforce by roughly 55%. The restructuring plan will result in 37 jobs being lost and the firm's Houston, USA site being close...

  • Financial Feasibility of Orphan Drugs Confirmed by Study

    Aug 22, 2012 Drugs developed to treat rare diseases have the potential to produce as much lifetime revenue as medication used for more common health conditions, according to a study published by Thomson Reuters yesterday. The report compared the total value of orphan drugs from 1990 to 2030 and found that gover...

  • Competition Warning for Eight NHS Trusts

    Aug 20, 2012 Eight NHS hospital trusts have provided guarantees to the Office of Fair Trading (OFT) that they will stop exchanging commercially-sensitive information about their Private Patient Unit (PPU) prices, and ensure that they conform to competition law. The Office of Fair Trading confronted members of t...

  • AstraZeneca Teams With Regulus' MicroRNA Therapeutics

    Aug 14, 2012 AstraZeneca has announced that they have entered into a strategic partnership with US biopharmaceutical group Regulus Therapeutics to discover, develop, and commercialise microRNA therapeutics. The Anglo-Swedish drug giant has agreed to pay $28 million, which includes an equity investment and an up...

  • Elan Separates Discovery Activities into Neotope

    Aug 12, 2012 Elan today has announced that they have decided to spin off of their discovery science and Neotope Biosciences divisions into a separate business entity “to create two independent, highly focused, public companies.” After the separation, Elan will hold three key assets: the multiple scl...

  • UK Branded Drug Pricing Arrangements from 2014

    Aug 07, 2012 The UK department of health and the ABPI (Association of the British Pharmaceutical Industry) have set the groundwork for discussions over the new pricing structure for medicines in the UK, which will come into force in 2014 after the current Pharmaceutical Price Regulation Scheme (PPRS) scheme fini...

  • Teva Profits Increased by US Generic Sales

    Aug 02, 2012 Teva Pharmaceutical Industries announced solid financials for the second quarter of 2012, improved by sales of their multiple sclerosis drug Copaxone, sturdy generics growth in the US and the contribution of Cephalon’s products. Net income increased by 50% to $863 billion, while sales grew 19...

  • Delay to Personal Health Budgets Called for by RCGP

    Jul 25, 2012 The Royal College of General Practitioners (RCGP) is calling for the brakes to be put on the scheduled release of personal healthcare budgets, as although they back the aim of the project, they still have apprehensions about the execution and potential for inequalities. Pilot schemes comprising of ...

  • GPs Account for Under Half of CCG Board Members

    Jul 23, 2012 GPs account for less than half of the available leadership roles in the emerging clinical commissioning groups (CCG) across England, igniting concerns that doctors are being pushed aside from the decision-making procedure on which services to offer patients. According to an enquiry by Pulse magazin...

  • Vifor and Grünenthal ‘Named and Shamed’ for Breaking ABPI Code

    Jul 09, 2012 Pharmaceutical companies Grünenthal and Vifor have been 'named and shamed' in numerous publications for breaking the Association of the British Pharmaceutical Industry's (ABPI’s) Code of Practice. Grünenthal has been criticised for the way in which their team of health economic liai...

  • Research Study Reveals Medication Warning Labels Require Overhaul

    Jul 05, 2012 Numerous patients appear to overlook prescription drug warning labels with directions that are vital for safe and effective use, a research study by scientists at Michigan State University and a Kansas State University researcher have found. Patients, predominantly older ones, frequently ignore pre...

  • Ferring Obtains Rights to Albireo’s Elobixibat

    Jul 03, 2012 Ferring Pharmaceuticals announced yesterday that they have acquired the rights of Albireo’s elobixibat, a first-in-class compound for chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). The arrangement provides Ferring with the rights to market the pr...

  • NHS Must Recognise and Enhance the Role of Generalists

    Jun 27, 2012 The important job of a ‘medical generalist’, or ‘expert in whole-person medicine’, needs to be more commonly acknowledged and improved if the NHS are to meet the challenges facing them, a new report published by the RCGP stresses. The importance and influence of medical gene...

  • Drug Shortages Experienced in 80% of NHS Trusts

    Jun 25, 2012 Eighty per cent of sixty National Health Service (NHS) trusts in England and Wales are facing “unacceptable” delays in locating drugs for patients, freedom of information requests by Labour MP Huw Irranca-Davies have exposed. About 70 to 80 drugs are still on the at risk list, including...

  • BAPW Urges Department of Health to Provide Leadership on Drug Shortages

    Jun 21, 2012 The Department of Health needs to “stop sticking its head in the sand” regarding the problem of drug shortages, the British Association of Pharmaceutical Wholesalers (BAPW) has stressed. “We work in a supply chain which presents many conflicting incentives, and we must have leader...

  • Pfizer's Xalkori Extends Lung Cancer Patient Survival

    Jun 19, 2012 Pfizer yesterday revealed information that demonstrates that Xalkori considerably improved progression-free survival in previously-treated patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). Xalkori (crizotinib) gained approval by the US Food and Dru...

  • Clinical Research 'Health Check' Tool for Trusts Introduced by NIHR

    Jun 13, 2012 The National Institute for Health Research Clinical Research Network (NIHR CRN) are introducing a new device to show National Health Service (NHS) Trusts in England how well they are delivering across different therapy areas on their responsibility to encourage clinical research trials. The initiat...

  • NHS Public Satisfaction Rates Tumble

    Jun 11, 2012 Public satisfaction regarding how the NHS functions across the UK dropped by 12% last year, to 58% from 70% in 2010, according to the most recent British Social Attitudes Survey. This is the largest decrease in one year from when the survey started in 1983, although it still remains the third highe...

  • Study Finds European Healthcare "Better Than Ever"

    Jun 07, 2012 In spite of the financial crisis, healthcare across Europe continues to improve, with consumer empowerment motivating advances in quality and access. However, the distribution of cancer drugs within the UK is still "deplorable," states a new review, presented at the European Parliament in Brussels....

  • Patient Support Programmes Create Better Results

    May 29, 2012 Patient support programmes (PSP) which involve patients paying part of the fee for their prescription drugs, provide better outcomes than programmes that allow patients to obtain their medication entirely free, eyeforpharma’s Patient Summit conference heard. Patient support programmes offer s...

  • Teva Reduces 2012 Profit Forecasts

    May 24, 2012 Teva Pharmaceuticals yesterday announced that they have reduced their sales and earnings predictions for 2012 partly as a result of pricing problems and currency effects in Europe. The organisation is now forecasting earnings in the range of $5.30-$5.40 per share, down from prior guidance of $5.48-...

  • Essential Drugs Unavailable as Greek Pharmacists Strike

    May 22, 2012 Approximately 163 critical drugs are now unobtainable from pharmacies in Greece, sector leaders stated, in advance of the country's pharmacists' planned one-day strike today. Drugstores in Greece are closed today as owners demonstrate against the fact that social security funds are yet to pay their...

  • Auranofin 'Promising' to Treat Amoebic Dysentery

    May 20, 2012 Auranofin, a common and cheap drug currently used for arthritis, could help fight against parasitic organisms responsible for amoebic dysentery, according to US researchers. Amoebic dysentery is caused by Entamoeba histolytica, which infects the bowels.  It results in severe diarrhoea as well ...

  • Campaigners Target Andrew Lansley at NICE Conference

    May 16, 2012 Unrest over the government’s health bill came to the fore again at this week’s NICE conference, with one protestor questioning the UK Health Secretary over his rejection to issue the NHS risk register during his speech to delegates yesterday. This is the second time that the Health Secr...

  • Merck KGaA Targets 300 Million Euros Cost Savings as Profits Fall

    May 14, 2012 Merck KGaA has revealed information regarding their new restructuring strategy and is targeting cost savings of 300 million euros at their drugs unit by 2014. Karl-Ludwig Kley, Chairman of the German organisation, noted that they face “unprecedented market shifts and increasing competition in...

  • NHS Could Save £350 Million Yearly From Generic Lipitor

    May 10, 2012 The admittance of generic forms of Pfizer's cholesterol lowering drug, Lipitor (atorvastatin), onto the UK market could in time save the NHS £350 million annually. According to the Generic Manufacturers' Association, the loss of Lipitor's patent protection in the UK and the accessibility of l...

  • UK Researchers Halt Brain Cell Death in Mice

    May 08, 2012 UK researchers have exposed the basis of what could become a new method to treat degenerative brain illnesses such as Alzheimer's and Parkinson's. Scientists from the University of Leicester have, by tackling a new pathway, managed to stop brain cell death in mice with prion disease, a progressive ...

  • MHRA Reveals New Strategy to Crack Down on Fake Drugs

    May 02, 2012 The MHRA (Medicines and Healthcare products Regulatory Agency), a government agency responsible for ensuring that medicines and medical devices work and are acceptably safe, has revealed their new anti-counterfeiting policy to increase the clamp down on fake drugs arriving in the UK supply chain. D...

  • Watson Pharmaceuticals Announces Strong First Quarter

    Apr 30, 2012 Watson Pharmaceuticals, which are currently in the procedure of acquiring generics firm Actavis for 4.25 billion euros, announced strong earnings and revenue increases for their first quarter on Monday. The company’s net income was up by 22% from $45.3 million to $54.8 million, while revenues...

  • Strong Vyvanse Sales Boost Shire’s First Quarter

    Apr 26, 2012 Shire posted another strong set of results yesterday, with a 20 percent rise in first-quarter earnings, just beating market expectations, and their attention-deficit hyperactivity disorder (ADHD) treatments and rare disease drugs once again performing well. Shire, whose development has outstripped ...

  • GlaxoSmithKline Announce Q1 Results

    Apr 24, 2012 Pharmaceutical drug maker, GlaxoSmithKline (GSK), today announced that their revenue increased just 1% in the first quarter, reflecting burdens on the organisation from government price cuts in Europe and some emerging markets, and hard year-by-year comparisons. GSK’s results were boosted by ...

  • The Department of Health Moves to Secure Quicker Access to Cancer Drugs Fund

    Apr 23, 2012 The Department of Health has issued new guidance on the Cancer Drugs Fund which, it says, should help National Health Service patients in England gain much faster access to innovative medicines. Launching the new guidance earlier this week, Health Minister Lord Howe commented that applications to t...

  • GlaxoSmithKline Retains Friendly Approach, Despite Hostile HGS Bid

    Apr 19, 2012 In confirming its unsolicited $2.60 billion offer for Human Genome Sciences (HGS), which was rejected, GlaxoSmithKline (GSK) commented that they still hope to push through the bid “on a friendly basis.” The UK drugs manufacturer noted that the $13.00 per share offer represented an 81% p...

  • Johnson & Johnson Profits Increase

    Apr 17, 2012 Johnson & Johnson (J&J) yesterday reported a 12.5% growth in earnings for their first quarter, assisted by sales of new products, the most noticeable being the prostate cancer drug Zytiga. The group’s net earnings came in at $3.91 billion, while turnover fell 0.2% to $16.14 billion.&n...

  • Only Medics’ Mobile Website Is Now Live

    Apr 15, 2012 To further enhance our services we today have launched our new mobile website, offering candidates an easier alternative when searching for their next pharmaceutical physician vacancy using their mobile. With an increasing number of people accessing the internet via their mobiles, Only Medics, as t...

  • Study Shows Huntington's Reduces Cancer Risk

    Apr 11, 2012 According to a study in Sweden, people who have developed Huntington's disease, a debilitating brain condition, appear have a "protection" from cancer. The findings, which were published in The Lancet Oncology, analysed almost 40 years of medical records, showing that patients with Huntington&rsquo...

  • Lansley Urges NHS Groups To Use New Power And Freedom To Innovate

    Apr 09, 2012 Over half of future NHS commissioning funds have already been delegated to clinical commissioning groups (CCGs), "and the number is rising all the time," Health Secretary Andrew Lansley has told CCG clinical and managerial leads. Mr Lansley wrote to Clinical Commissioning Groups highlighting the fr...

  • Eisai Joins Up With Valeant To Promote Halaven

    Apr 03, 2012 After failing to gain approval from UK cost watchdog, NICE, for the use of Halaven in treating breast cancer, Eisai has linked up with Valeant Pharmaceuticals International, to promote the drug in Central and Eastern Europe. Halaven received European Commission approval in March 2011. Valeant's Ph...

  • Court of Justice Finds Poland's Low-cost Treatment Law Breaks EU Rules

    Apr 01, 2012 The EU Court of Justice ruled on Thursday last week that a Polish law which allows the sale of prescription medicine that has not been permitted by the European Medicines Agency (EMA) but is similar and cheaper to drugs which have, breaches European Union (EU) law. Under European law, no prescripti...

  • Boehringer Ingelheim Reduces Cost of Pradaxa by 13%

    Mar 28, 2012 Boehringer Ingelheim has announced that they will be decreasing the price of their oral anticoagulant Pradaxa (dabigatran etexilate) by 13% to £2.20 per day, from 1st April 2012. The change comes two weeks after the National Institute for Health and Clinical Excellence (NICE) issued a final g...

  • UK Government Increases Funding For Dementia Research

    Mar 26, 2012 The UK government has pledged to more than double annual funding for research into dementia and neurodegenerative diseases to over £66 million by 2014/15, in an increase from £26.6 million in 2009/10. The commitment was announced yesterday by the UK Prime Minister, David Cameron, as par...

  • Lung Cancer Detection Trial Announced For Smokers

    Mar 23, 2012 A simple blood test which can identify lung cancer five years before conventional screenings will be trialled by the NHS on 10,000 high risk smokers. The trial is being tested in Scotland in the anticipation that it could provide the first national screening programme for lung cancer in addition to...

  • UK MPs Approve Controversial NHS Bill

    Mar 21, 2012 The NHS health bill has survived the final parliamentary test and is set to become law. Labour’s call for MPs to delay their final consideration of the NHS overhaul in England until an evaluation of the potential risks is available was defeated by 82 votes. An emergency debate over the propo...

  • Medicine Access Changes Will Help Companies Develop, UK MPs Told

    Mar 15, 2012 UK MPs have been told that regulatory proposals currently being considered for quicker entrance for medicines which meet key unmet medical needs provide an opportunity for small life science businesses to grow to middle-sized organisations. In December 2011, the UK’s Prime Minister, David Cam...

  • Pharmaceutical Industry is 'Safe Haven' for Investors

    Mar 13, 2012 Analysts at Peel Hunt have analysed the global healthcare sector, and stated that it is in a fairly healthy condition, in spite of the pressures the industry is currently under. Contained within the report, the broker claims that the healthcare sector "has again proved its resilience in periods of ...

  • Pharmaceutical Industry Should Invest Further in Anti-Obesity Drugs

    Mar 09, 2012 Pharmaceutical organisations should increase their investment in anti-obesity drugs to respond to the rising number of clinically obese people globally. This is the main message from a report by business intelligence specialist, GlobalData, which observes that the obesity market is lucrative, large...

  • ICON’s MIRA Chosen by Roche for Medical Image Repository

    Mar 07, 2012 Continuing its move from transactional relationships to strategic alliances with clients, ICON have announced that they have been chosen by Roche as Roche’s technology partner for storing and managing medical images collected during clinical research programmes. ICON is an international suppl...

  • Only Medics To Attend DGPharMed 2012

    Mar 05, 2012 Only Medics will be attending DGPharMed’s annual conference at the Hotel Pullman Cologne, in Germany on the 8th and 9th March 2012.2012 sees the 28th year of the annual conference by the German Society of Pharmaceutical Medicine.The conference starts at 9:20am on Thursday 8th March, and finish...

  • UK’s NICE Dismisses Drug Delay Statements

    Mar 01, 2012 The UK’s National Institute for Health and Clinical Excellence (NICE) has not been requested to alter the basis of their assessments "simply to save money," NICE’s chief executive, Sir Andrew Dillon, has stated. Sir Andrew Dillon was replying to media reports from earlier this week, whi...

  • Only Medics at the 2012 BrAPP Annual Symposium

    Feb 28, 2012 Only Medics will be attending this year’s BrAPP Conference on 1st March 2012 in London.2012 sees BrAPP celebrating its 55th year as the professional association for pharmaceutical physicians.The conference starts at 9am, and is followed by a three course dinner with guest speaker, Professor Tr...

  • Study Finds Selected Dementia Antipsychotics Raise Death Risks

    Feb 24, 2012 Nursing home residents over 65 who take certain antipsychotics for dementia are at an increased risk of death, according to a recent study by the Harvard Medical School involving 75,445 patients. In a paper published on bmj.com, the study, which was the largest ever undertaken among US nursing home...

  • Berkeley Lab Discover New Evidence On How ‘Good’ Cholesterol Turns ‘Bad’

    Feb 22, 2012 Researchers with the U.S. Department of Energy's Lawrence Berkeley National Laboratory (Berkeley Lab) have discovered new proof to clarify how cholesteryl ester transfer protein (CETP) mediates the move of cholesterol from "good" high density lipoproteins (HDLs) to "bad" low density lipoproteins (LD...

  • Health Inequalities Increase, As Experts Warn Over Health Plans

    Feb 16, 2012 Two years after the Marmot Review Fair Society, Healthy Lives was released, new data revealed yesterday illustrates that health inequality between the poor and the rich are continuing to grow, although there has been an improvement in average life expectancy.According to figures from the Institute o...

  • US green light for Merck & Co's eye drug Zioptan

    Feb 14, 2012   The US Food and Drug Administration has given the nod to Merck & Co's eye solution Zioptan for lowering intraocular pressure in patients with certain eye conditions. Shares in the drugmaker were given a bump after it announced that Zioptan (tafluprost ophthalmic solution) 0.0015%...

  • Eisai Receives Positive Alzheimer Study Results, While FDA Rejects Dacogen

    Feb 10, 2012 Eisai has received mixed news this week, after news that Dacogen, Eisai and Astex Pharmaceuticals’ drug to treat a type of leukaemia, has been rejected by an independent advisory panel to the regulator in the USA.The US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Commit...

  • Osteoporosis Market Predicted To Grow To $11.4B By 2015

    Feb 08, 2012 The global market for osteoporosis drugs is expected to increase from $7.3 billion in 2010 to $11.4 billion by 2015, according to new estimates. The market will achieve an average annual growth of 9.2% during this period, according to the report published by Transparency Market Research. The stud...

  • Competition Could Benefit the NHS, Declares the Office of Health Economics

    Feb 02, 2012   Competition can help the integration of care in the NHS, and there is no proof that it would hinder it, according to a new report from the Office of Health Economics. The report analyses the conclusions of the Commission on Competition in the NHS, which was assembled by the OHE (Office of...

  • New Children's Health Outcomes Strategy Planned By UK Government

    Jan 31, 2012 The UK government has revealed new plans for a focus to improve health care for children and young people.The ‘Children's and Young People's Outcomes Strategy’, which will be unveiled later in the year, will concentrate on improving healthcare service outcomes for children, including tho...

  • Our Latest Advert in BrAPP January 2012

    Jan 26, 2012 Our newest advert has been published in the latest issue of BrAPP's Pharmaceutical Physician Magazine. It can be downloaded in our Brochure and latest adverts section. Tell us what you think!...

  • Frost & Sullivan Study Finds Major Development Potential for European CMOs

    Jan 25, 2012 The European pharmaceutical contract manufacturing market made revenues of $10.02 billion in 2011, and this figure is expected to double to $20.75 billion by 2018, according to new forecasts.Over the same time period, the European market for biotechnology contract manufacturing is expected to increa...

  • BAPW Appeal for Objective Monitoring of Branded Medicine Supplies

    Jan 19, 2012 The BAPW (British Association of Pharmaceutical Wholesalers) has appealed for pharmacies and manufacturers to support third-party monitoring and reporting of branded drug supplies.Critical deliberation should be given to the establishment of a robust, objective monitoring and survey service of medic...

  • Hospital Patient Service Cuts Are Hard To Defend, Says Nuffield Trust Report

    Jan 17, 2012 Cuts in patient services are difficult to rationalise when there are many ways hospitals could improve their efficiency, a major new evaluation prepared for the Nuffield Trust by Jeremy Hurst and Sally Williams has concluded.While inefficiencies in areas such as rates of day case surgery, length of ...

  • Investigative Sites Continued to Shrink Over Last Five Years

    Jan 11, 2012 The international landscape for investigative sites, research centres that conduct clinical research, has continued to decline over the past five years, according to US-based information services provider CenterWatch.The global economic downturn is combining with decreasing study numbers, budget pre...

  • European GPs Are Concerned That Health Systems Will Fail As Population Ages

    Jan 05, 2012 Roughly 80% of doctors are concerned about how they will be treated when they grow old and fear that present guidelines to deal with the ageing population are not "comprehensive, realistic or sufficiently funded to address future demand".That is one of the main findings of a recent study from the Ec...

  • "Choose your GP" Pilots Announced for April

    Jan 03, 2012 UK Health Secretary, Andrew Lansley, has announced that one-year pilot schemes for a new initiative which allow patients to choose their GP practice will start in April this year. The trials, which will run in parts of central London, Manchester/Salford and Nottingham, will allow the public, for ...

  • European Proposals Would "Give More Scope for Negotiation" says the NHS

    Dec 22, 2011 The EU’s (European Union) proposal for a new directive on public procurement will permit "more scope for negotiating with suppliers," according to the NHS Confederation. The plans, which have been published by the European Commission this week, contain a number of provisions intended to sim...

  • Multiple Myeloma Therapy Market Set For "Robust" Annual Growth

    Dec 21, 2011 The multiple myeloma drug therapy market will experience robust growth averaging 5.6% annually from 2010 to 2020 in seven of the world’s major markets, according to new projections. Growth in these markets - US, Italy, Spain, UK, France, Germany and Japan - will be driven by additional pene...

  • Merry Christmas, from the Only Medics Team

    Dec 20, 2011 We would like to wish all of Only Medics' clients and candidates a very Merry Christmas and Best Wishes for the New Year. Thank you for your business in 2011 and we look forward to working with you in 2012!Please note the following office hours:Only Medics will be closed from midday on Friday, 23r...

  • NHS To Receive £2.5 Billion Funding Boost for 2012-2013

    Dec 20, 2011 The NHS is to gain a funding boost of over £2.5 billion to deliver services to patients in 2012-13, Health Secretary Andrew Lansley has announced. £91.6 billion will be given to Primary Care Trusts, representing a 2.8% rise in total allocations.  The funding breaks down as follow...

  • Galapagos Reaches Milestone in Servier Osteoarthritis Agreement

    Dec 16, 2011 Galapagos of Belgium yesterday announced that they have reached milestones in its osteoarthritis alliance with Servier, resulting in a payment of 4 million euros from the French drugmaker.In July 2010, teamed up for a collaboration that could be worth around 300 million euros to the Mechelen-based g...

  • Challenging 2012 Predicted for the Pharmaceutical Industry

    Dec 15, 2011 Ratings agency Fitch has issued a report predicting that the pharmaceutical sector will "continue to experience significant operating challenges" in 2012 but while issuing a negative outlook, they added that pharmaceuticals will still be one of the highest-rated industries. The new analysis comme...

  • UK Audit Finds That Lung Cancer Care is Improving Every Year

    Dec 13, 2011 The National Lung Cancer Audit announced that the proportion of patients receiving key care measures, such as surgery or anti-cancer treatment like chemotherapy or radiotherapy, is improving each year.58.4% of patients with lung cancer in England and Wales and 63.9% in Scotland received an anti-canc...

  • Haemophilia B Gene Therapy Injection Shows Initial Success

    Dec 12, 2011 A small trial which shows that symptoms improved considerably in adults with the bleeding disorder haemophilia B, after a single treatment with gene therapy, has caused excitement among the scientific community.A single treatment with gene therapy developed by researchers at St Jude Children's Resea...

  • Only Medics' Sister Company, Clinical Professionals, Achieves Sunday Times Fast Track 100 Top 50 Ranking

    Dec 12, 2011 Fast Track, in association with the Sunday Times, has this week revealed Britain’s fastest growing private firms. Only Medics' sister company, Clinical Professionals, was ranked in the Top 50 within The Sunday Times Virgin Fast Track 100 league table for 2011.The league table ranks Britain&rsq...

  • Johnson & Johnson To Pay Nearly $1 Billion for Pharmacyclics' Cancer Drug

    Dec 09, 2011 Johnson & Johnson have entered into an agreement to help develop a cancer compound discovered by Pharmacyclics in a deal that could be worth close to $1 billion to Pharmacyclics.Johnson & Johnson's Janssen Biotech subsidiary will work together to develop and market the drug, known as PCI-327...

  • Roche Set Up Swiss Academic Translational Centre

    Dec 08, 2011 Roche yesterday announced that they are increasing their collaborative efforts with academic researchers to deliver the next generation of targeted therapies for unmet medical needs by creating an external academic translational research hub in their home market. The hub in Zurich, Switze...

  • Lifestyle Choices Cause More Than 100,000 Cancers Each Year

    Dec 07, 2011 A report by Cancer Research has revealed that 40% (100,000) of cancers diagnosed annually in the UK are caused by a person's lifestyle choice and could potentially have been prevented.  The main causes of the cancers included smoking, eating the wrong type of daily diet, and drinking alcohol.Th...

  • Pharmaceutical Industry Receives Boost from UK Government Plans to Improve Medicine Access

    Dec 06, 2011 Earlier access to new medicines and automatic inclusion of NICE-recommended treatments onto local formularies are some of the many measures included in a package announced yesterday by the UK Prime Minister, David Cameron, as part of the UK's Life Sciences Strategy and the NHS Chief Executive, Sir D...

  • Eli Lilly Conduct Study into the Barriers of Progression in Insulin Treatment

    Dec 02, 2011 Eli Lilly and Company yesterday announced that they are conducting the first major international, prospective observational study intended to understand the real-world difficulties that people with type 2 diabetes face that result in preventing them from attainment their ultimate treatment goals. ...

  • NHS Urge Improved Joint Working with Pharma

    Dec 01, 2011 Joint working with pharmaceutical companies should be "explicitly" positioned as an enabler of clinical commissioning, according to the NHS. The ethos and local emphasis of the NHS / industry joint working initiatives are closely aligned with the values of clinical commissioning, and their foc...

  • Pharmaceutical Google+ Pages

    Nov 21, 2011 As Google+ becomes a more integrated part of our on-line searches, we thought we would list here the major Pharmaceutical companies with a dedicated page up on the network. Adding them to your circles will allow you to follow their latest research updates as well as any developments the pharmace...

  • Only Medics now on Google+

    Nov 09, 2011 Only Medics have recently created a dedicated page on Google+ Add us to your circles to be kept up to date on the latest careers and industry news for pharmaceutical physicians. Only Medics are the forefront of their field, of which we hope this we become another useful networking and informatio...

  • New Only Medics Article - The Interim

    Nov 07, 2011 Following on from our successful line of articles, a pharmaceutical physician from the industry has written an article for us on the subject of Interims. A very insightful read for those looking to move their career in this direction or wishing to know more information on the topic. Just head to...

  • Latest BrAPP Advert now Published (September 2011)

    Sep 11, 2011 Following on from our new set of advert designs, our new BrAPP advert is now live. Read the latest issue of Pharmaceutical Physician to see it in print, or download it from the 'Brochure and Latest adverts' Section of the website....

  • Social Media Focus

    Jul 25, 2011 Only Medics continues to see an increase in group numbers for our social media groups. We now have a number of groups on LinkedIn and a Twitter group to assist candidates looking for employment. After becoming one of the first pharmaceutical recruitment companies to network using LinkedIn grou...

  • Only Medics in the National Online Recruitment Awards 2011

    Jun 23, 2011 Only Medics have recently been entered in for the National Online Recruitment Awards, NORA. Established in 2001, NORA reward the excellence in the UK online recruitment process, that has been unparalleled anywhere else in the world. We are delighted to be a part of these prestigious awards,...

  • New Website now Live.

    Jun 01, 2011 After Months of Planning and feedback from Only Medics and our clients and contacts we are proud to present our new website. We feel it is a vast improvement on the old structure, and allows for much easier navigation and focus on the areas important to yourselves. We hope we continue to be a us...

  • Latest BrAPP Advert now Published (May 2011)

    May 18, 2011 Our latest BrAPP advert is was very warmly received in the latest issue of Pharmaceutical Physician. It is now also available as a PDF download in our Brochure and Adverts section....

  • Latest BrAPP Advert now Published (March 2011)

    Feb 09, 2011 Our latest advert to be published in the BrAPP pharmaceutical Physician Magazine is now available in the Brochure and Adverts section of the website....

Job Search

Advanced job search

Register your C.V.

News

Testimonials